Advertisement
Australia markets closed
  • ALL ORDS

    8,015.80
    +72.20 (+0.91%)
     
  • AUD/USD

    0.6642
    +0.0029 (+0.44%)
     
  • ASX 200

    7,778.10
    +77.80 (+1.01%)
     
  • OIL

    80.54
    +0.21 (+0.26%)
     
  • GOLD

    2,331.50
    +2.50 (+0.11%)
     
  • Bitcoin AUD

    97,369.17
    -1,105.13 (-1.12%)
     
  • CMC Crypto 200

    1,347.70
    -41.70 (-3.00%)
     

Horizon Technology Finance Corp (HRZN) Q1 2024 Earnings Call Transcript Highlights: Key ...

  • Portfolio Size: Grew slightly to $711 million.

  • Debt Investments Funded: $33 million across five debt investments.

  • Loan Prepayments and Refinances: Totaling $20 million.

  • Debt Portfolio Yield: 15.6% for the quarter.

  • Warrant and Equity Positions: Held in 99 companies, fair value of $31 million.

  • New Loan Commitments: Closed at $37 million.

  • Committed and Approved Backlog: $168 million.

  • Investment Income: $26 million for the quarter.

  • Net Investment Income (NII) Per Share: $0.38.

  • Net Asset Value (NAV) Per Share: $9.64 as of March 31.

  • Total Investment Portfolio: $711 million.

Release Date: May 01, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

  • Horizon Technology Finance Corp (NASDAQ:HRZN) reported a slight growth in portfolio size to $711 million in Q1, indicating stable business expansion.

  • The company continues to generate strong net investment income (NII), which has consistently covered distributions for over six years, showcasing financial stability.

  • HRZN's debt portfolio yield of 15.6% for the quarter remains one of the highest in the BDC industry, reflecting the profitability of their venture lending strategy.

  • The company has maintained a robust pipeline with $1.8 billion in potential deals, demonstrating strong market demand and reputation.

  • HRZN has a solid liquidity position with $91 million available, providing ample capacity for future investments and operational flexibility.

Negative Points

  • Challenges in the venture capital environment persist, with a notable decline in VC investment in later-stage companies by 36% from the previous year.

  • HRZN experienced a decrease in investment income to $26 million from $28 million in the prior period, primarily due to lower interest income on debt investments.

  • The company faces increased competition in the venture debt market, particularly from larger players with more aggressive pricing strategies.

  • There are ongoing concerns with unrealized losses in the portfolio, indicating potential valuation issues and investment risks.

  • HRZN's net asset value (NAV) per share decreased to $9.64 from $9.71 in the previous quarter, reflecting some pressures on asset valuations.

Q & A Highlights

Q: Could you discuss the write-up of the Evelo investment and the significant write-down quarter over quarter? A: Gerald Michaud, President, Director - After a failed clinical trial, the market was quite depressed, leading to a conservative valuation around $1 million. However, there's ongoing work to maximize the value of Evelo's assets, with potential positive developments expected in the next quarters.

ADVERTISEMENT

Q: Can you provide an update on the additional nonaccruals and the related fair value marks? A: Daniel Devorsetz, COO, EVP, CIO - Both companies on nonaccrual have potential value in their technology and business assets, with third-party interest. Efforts are ongoing to maximize recoveries, which might take a quarter or two more to materialize.

Q: What is the mix between existing companies and new platform companies in the backlog, and what are the expectations for repayment activity? A: Daniel Devorsetz, COO, EVP, CIO - The backlog primarily consists of committed milestones to existing borrowers. Originations are slow as the company is cautious, ensuring only high-quality venture debt investments are funded.

Q: What caused the lower interest income this quarter? A: Daniel Trolio, CFO, EVP, Treasurer - The lower interest income was due to a combination of lower portfolio size, decreased prepayment activity, and the absence of fee accelerations that typically accompany repayments.

Q: Are convertible transactions or preferred capital competing with venture debt markets? A: Gerald Michaud, President, Director - These equity solutions are not in competition but are often part of a broader financing mix that includes venture debt. The market is seeing more realistic equity contributions, which helps in structuring supportive venture debt arrangements.

Q: How are you competing with larger players in the venture debt market? A: Gerald Michaud, President, Director - Horizon competes effectively on price and can manage size constraints through strategic capital raising and collaborations, especially with tech banks post-SVB crisis, allowing competitive and attractive financing solutions.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.